{
  "docId": "019de072-a701-779d-b9c1-29622b36dd41",
  "docSlug": "f2c95dae10c304072442cd11deed84ec",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 53 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 30,
  "pageCount": 53,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a structured list format to categorize R&D and commercial progress by business unit.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de072-a701-779d-b9c1-29622b36dd41/30",
  "deckHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41",
  "deckJsonHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41.json",
  "deckAnchorHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.72,
        "x": 0.24,
        "y": 0.62
      },
      "kind": "list",
      "text": "Ortho Dermatologics: IDP-120 and IDP-126 status updates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7c6392a-fcc4-4e00-9afd-96e84b5be382",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.72,
        "x": 0.24,
        "y": 0.48
      },
      "kind": "list",
      "text": "International: Expect to launch ~45 products across 50 markets in the next 5 years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0f1aadc-b012-49cf-85aa-97c4dffdb856",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.72,
        "x": 0.24,
        "y": 0.22
      },
      "kind": "list",
      "text": "Bausch Pharma/Solta Medical: Amiselimod S1P2 Modulator, Rifaximin SSD, Rifaximin ER/DER, Rifaximin (SIBO)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4997809-464b-401b-85dc-c0a8608f92a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.72,
        "x": 0.24,
        "y": 0.78
      },
      "kind": "list",
      "text": "Solta Medical: Clear + Brilliant Touch launch and geographic expansion plans",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faacf044-e643-4fbc-bb6f-a577c3270b3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.27,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. See slide 1 for further information on forward-looking statements. 2. Sphingosine 1-phosphate. 3. Exclusive licensing agreement with Mitsubishi Tanabe Pharma. 4. Hepatic encephalopathy. 5. Small intestinal bacterial overgrowth.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a74a7a83-b0d4-4f9d-b574-78206554aee9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.17,
        "y": 0.05
      },
      "kind": "title",
      "text": "Progress in Late-Stage Product Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7c81660-d88d-4d31-b041-b05a7d50c9f7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f16cf5e2-8f44-4e33-9a27-ff43ed3949d4",
      "evidence": "list/bullet: Bausch Pharma/Solta Medical: Amiselimod S1P2 Modulator, Rifaximin SSD, Rifaximin ER/DER, Rifaximin (SIBO)",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}